MNV
Market News Video
MNV MNV 10 Stocks Crossing Below Book Value
MNV
MNV
MNV
MNV
MNV
MNV
MNV
Free Dividend Report - Top Ranked Stocks

Featured MNV Articles:

Skyworks Solutions Achieves #50 Analyst Rank, Surpassing Vertex Pharmaceuticals
Friday, November 10, 11:47 AM ET, by Market News Video Staff

In a study of analyst recommendations at the major brokerages, for the underlying components of ...

Kellogg Moves Up In Market Cap Rank, Passing Agilent Technologies
Wednesday, November 22, 4:40 PM ET, by Market News Video Staff

In the latest look at the underlying components of the S&P 500 ordered by largest ...

Agree To Buy Vertex Pharmaceuticals At $110, Earn 10.4% Using Options
Tuesday, December 5, 11:27 AM ET, by Market News Video Staff

Investors considering a purchase of Vertex Pharmaceuticals, Inc. (VRTX) shares, but cautious about paying the ...

The Implied Analyst 12-Month Target For XLV
Thursday, December 7, 8:32 AM ET, by Market News Video Staff

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, ...

Vertex Pharmaceuticals Takes Over #158 Spot From Twenty-First Century Fox
Friday, December 8, 4:56 PM ET, by Market News Video Staff

In the latest look at the underlying components of the S&P 500 ordered by largest ...

  More articles:  1 2 next »

CGEN Makes Bullish Cross Above Critical Moving Average

By Market News Video Staff, Tuesday, May 17, 1:27 PM ET
Play Video: Learn About The 200 DMA


If the video does not load after a few moments, Upgrade to the Latest Flash Player.

In trading on Tuesday, shares of Compugen Ltd (NASDAQ:CGEN) crossed above their 200 day moving average of $4.66, changing hands as high as $4.77 per share. Compugen Ltd shares are currently trading trading flat on the day. The chart below shows the one year performance of CGEN shares, versus its 200 day moving average:

Compugen Ltd 200 Day Moving Average Chart

Looking at the chart above, CGEN's low point in its 52 week range is $3.04 per share, with $5.80 as the 52 week high point that compares with a last trade of $4.56.

CGEN operates in the Biotechnology sector, among companies like Vertex Pharmaceuticals, Inc. (NASDAQ:VRTX) which is down about 0.7% today, and Agilent Technologies, Inc. (NYSE:A) trading lower by about 2.6%. Below is a three month price history chart comparing the stock performance of CGEN, versus VRTX and A.

CGEN,VRTX,A Relative Performance Chart


Free Trial: ''ETF CHANNEL FLEXIBLE GROWTH INVESTMENT PORTFOLIO''

The ETF Channel Flexible Growth Investment Portfolio is designed to seek growth for investors anywhere and everywhere. The key to the program is our portfolio strategy allows us complete flexibility in terms of asset allocation as there are no predetermined guidelines as to the level of stocks, bonds, cash, regions, countries, sectors, commodities, or even asset classes in the portfolio! In short, this is a completely flexible portfolio designed to follow the performance trail wherever it leads us.


This Article's Word Cloud:   Above   Agilent   Average   Below   Biotechnology   CGEN   Channel   Compugen   Crossing   Flexible   Free   Growth   Investment   Looking   Moving   NYSE   Pharmaceuticals   Portfolio   Start   Stocks   Technologies   Their   Trial   Tuesday   VRTX   Vertex   about   above   allocation   allows   among   anywhere   asset   average   below   bonds   cash   chart   designed   high   moving   performance   point   portfolio   share   shares   trading   versus   week   with
MNV
MNV
About Us - Advertise - Contact Us - Embedding Videos - Licensing Videos - Partners - mRSS / RSS Feed - Terms of Use - Privacy Policy
MNV
Home  |  Analyst News  Dividend Report  ETFs  Insider Report  Large Caps  Market Movers  Week Ahead Report  Weekly Market Wrap
MNV
MNV MNV Chart Zero Stock Market Game Stock Market Definitions
MNV

CGEN Makes Bullish Cross Above Critical Moving Average | Market News Video | Copyright © 2008 - 2018, All Rights Reserved

Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners. In no way should any content contained herein be interpreted to represent trading or investment advice. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.